Cargando…

Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway

Myricetin (Myr) is a common plant-derived polyphenol and is well recognized for its multiple activities including antioxidant, anti-inflammation, anticancer, and antidiabetes. Our previous studies indicated that Myr protected mouse heart from lipopolysaccharide and streptozocin-induced injuries. How...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Hai-han, Zhang, Nan, Meng, Yan-yan, Feng, Hong, Yang, Jing-jing, Li, Wen-jin, Chen, Si, Wu, Hai-ming, Deng, Wei, Tang, Qi-zhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925812/ https://www.ncbi.nlm.nih.gov/pubmed/31885808 http://dx.doi.org/10.1155/2019/6304058

Ejemplares similares

The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling
por: Ji, Yan-Xiao, et al.
Publicado: (2016)

Protections of transcription factor BACH2 and natural product myricetin against pathological cardiac hypertrophy and dysfunction
por: Jiang, Xueli, et al.
Publicado: (2022)

SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1‐Dependent Manner
por: Qian, Qiaofeng, et al.
Publicado: (2023)

Cardiomyocyte-Specific RIP2 Overexpression Exacerbated Pathologic Remodeling and Contributed to Spontaneous Cardiac Hypertrophy
por: Yang, Jing-jing, et al.
Publicado: (2021)

Dual‐Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1
por: Zhao, Jing, et al.
Publicado: (2021)

Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
por: Deng, Ke-Qiong, et al.
Publicado: (2016)

GCN5-mediated regulation of pathological cardiac hypertrophy via activation of the TAK1-JNK/p38 signaling pathway
por: Li, Jia, et al.
Publicado: (2022)

Andrographolide Protects against Aortic Banding-Induced Experimental Cardiac Hypertrophy by Inhibiting MAPKs Signaling
por: Wu, Qing Q., et al.
Publicado: (2017)

Ubiquitin‐specific protease 19 blunts pathological cardiac hypertrophy via inhibition of the TAK1‐dependent pathway
por: Miao, Rujia, et al.
Publicado: (2020)

Myricetin Possesses Potential Protective Effects on Diabetic Cardiomyopathy through Inhibiting IκBα/NFκB and Enhancing Nrf2/HO-1
por: Liao, Hai-han, et al.
Publicado: (2017)

Corrigendum to “Myricetin Possesses Potential Protective Effects on Diabetic Cardiomyopathy through Inhibiting IκBα/NFκB and Enhancing Nrf2/HO-1”
por: Liao, Hai-han, et al.
Publicado: (2021)

Liquiritin Attenuates Pathological Cardiac Hypertrophy by Activating the PKA/LKB1/AMPK Pathway
por: Aiyasiding, Xiahenazi, et al.
Publicado: (2022)

Author Correction: Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy
por: Deng, Ke-Qiong, et al.
Publicado: (2023)

TRAF Family Member 4 Promotes Cardiac Hypertrophy Through the Activation of the AKT Pathway
por: Li, Jian, et al.
Publicado: (2023)

Garlic Oil Alleviates MAPKs- and IL-6-mediated Diabetes-related Cardiac Hypertrophy in STZ-induced DM Rats
por: Chang, Sheng-Huang, et al.
Publicado: (2011)

Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling
por: Wang, Pi-Xiao, et al.
Publicado: (2016)

TRAF3 mediates neuronal apoptosis in early brain injury following subarachnoid hemorrhage via targeting TAK1-dependent MAPKs and NF-κB pathways
por: Zhou, Yan, et al.
Publicado: (2021)

Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling
por: Tomomura, Mineko, et al.
Publicado: (2015)

Delphinidin attenuates pathological cardiac hypertrophy via the AMPK/NOX/MAPK signaling pathway
por: Chen, Youming, et al.
Publicado: (2020)

Nicotinamide Riboside Alleviates Cardiac Dysfunction and Remodeling in Pressure Overload Cardiac Hypertrophy
por: Ma, Sai, et al.
Publicado: (2021)

(+)-Vitisin A Inhibits Osteoclast Differentiation by Preventing TRAF6 Ubiquitination and TRAF6-TAK1 Formation to Suppress NFATc1 Activation
por: Chiou, Wen-Fei, et al.
Publicado: (2014)

Periplocymarin alleviates pathological cardiac hypertrophy via inhibiting the JAK2/STAT3 signalling pathway
por: Fan, Cai‐lian, et al.
Publicado: (2022)

Arginyltransferase knockdown attenuates cardiac hypertrophy and fibrosis through TAK1-JNK1/2 pathway
por: Singh, Kanika, et al.
Publicado: (2020)

NULP1 Alleviates Cardiac Hypertrophy by Suppressing NFAT3 Transcriptional Activity
por: Zhang, Xin, et al.
Publicado: (2020)

TRAF-STOP alleviates osteoclastogenesis in periodontitis
por: Huang, Yaxian, et al.
Publicado: (2023)

Cilostazol alleviate nicotine induced cardiomyocytes hypertrophy through modulation of autophagy by CTSB/ROS/p38MAPK/JNK feedback loop
por: Wang, Shu-ya, et al.
Publicado: (2020)

Interleukin-1 and TRAF6-dependent activation of TAK1 in the absence of TAB2 and TAB3
por: Zhang, Jiazhen, et al.
Publicado: (2017)

TAB3 upregulates Survivin expression to promote colorectal cancer invasion and metastasis by binding to the TAK1-TRAF6 complex
por: Luo, Chen, et al.
Publicado: (2017)

Tomoregulin-1 prevents cardiac hypertrophy after pressure overload in mice by inhibiting TAK1-JNK pathways
por: Bao, Dan, et al.
Publicado: (2015)

Norisoboldine Suppresses Osteoclast Differentiation through Preventing the Accumulation of TRAF6-TAK1 Complexes and Activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways
por: Wei, Zhi-feng, et al.
Publicado: (2013)

Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy
por: Zhen, Changlin, et al.
Publicado: (2023)

Fibroblast growth factor 18 alleviates stress-induced pathological cardiac hypertrophy in male mice
por: Chen, Gen, et al.
Publicado: (2023)

Knockout of AMPKα2 Blocked the Protection of Sestrin2 Overexpression Against Cardiac Hypertrophy Induced by Pressure Overload
por: Zhang, Nan, et al.
Publicado: (2021)

Cryptotanshinone Attenuated Pathological Cardiac Remodeling In Vivo and In Vitro Experiments
por: Li, Wen-jing, et al.
Publicado: (2023)

TTRAP Is a Novel Component of the Non-Canonical TRAF6-TAK1 TGF-β Signaling Pathway
por: Várady, György, et al.
Publicado: (2011)

TRAF6 and TAK1 Contribute to SAMHD1-Mediated Negative Regulation of NF-κB Signaling
por: Espada, Constanza E., et al.
Publicado: (2021)

Author Correction: Arginyltransferase knockdown attenuates cardiac hypertrophy and fibrosis through TAK1-JNK1/2 pathway
por: Singh, Kanika, et al.
Publicado: (2020)

Functions of Autophagy in Pathological Cardiac Hypertrophy
por: Li, Zhenhua, et al.
Publicado: (2015)

VCP represses pathological cardiac hypertrophy
por: Zhou, Ning, et al.
Publicado: (2017)

Design, synthesis and evaluation of a myricetin and nobiletin hybrid compound for alleviating hyperuricemia based on metabolomics and gut microbiota
por: Li, Yan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_av8vd66sumjocv70g35s0o175j